Clinical Trials Logo

Clinical Trial Summary

The present study proposes a new and potentially superior clinical approach to Optuneā„¢ therapy of selected glioblastoma patients. The approach is based on combining TTFields with targeted surgical skull remodeling, such as minor craniectomy or a distribution of burr holes, designed for the individual patient. Pre-clinical modeling results suggest that such procedures may enhance the induced electrical field strength by up to ~100% and thereby potentially improve the clinical outcome of treated patients to a significant extent.

The study is an open label phase 1 clinical pilot experiment designed to investigate feasibility, safety and efficacy of the concept. Fifteen patients with first recurrence of glioblastoma will be included in the trial. All patients will receive TTFields therapy with targeted craniotomy and best physician's choice chemotherapy.


Clinical Trial Description

n/a


Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT02893137
Study type Interventional
Source University of Aarhus
Contact Anders R Korshoej, MD
Email andekors@rm.dk
Status Recruiting
Phase Phase 1
Start date October 2016

See also
  Status Clinical Trial Phase
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in People With Metastatic Cancer Phase 2
Suspended NCT02768389 - Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma Early Phase 1
Completed NCT01250470 - Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma Phase 1
Not yet recruiting NCT03661723 - Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma Phase 2
Not yet recruiting NCT03422094 - Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma Phase 1
Recruiting NCT03587038 - OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy for Newly Diagnosed Glioblastoma Phase 1
Recruiting NCT03493932 - Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade Phase 1
Recruiting NCT01813877 - Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma N/A
Recruiting NCT03679754 - Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102 Phase 1
Recruiting NCT03278249 - Feasibility Study of Modified Atkins Ketogenic Diet in the Treatment of Newly Diagnosed Malignant Glioma N/A
Recruiting NCT02709889 - Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors Phase 1/Phase 2
Completed NCT02905643 - Discerning Pseudoprogression vs True Tumor Growth in GBMs
Withdrawn NCT02876003 - Efficacy and Safety of G-202 in PSMA-Positive Glioblastoma Phase 2
Active, not recruiting NCT02366728 - DC Migration Study for Newly-Diagnosed GBM Phase 2
Recruiting NCT01985087 - A Study Using Radiation Therapy and Temozolomide to Treat Glioblastoma in Patients Over 70 Phase 1/Phase 2
Withdrawn NCT01622764 - 89Zr-RO5323441 PET Imaging in Glioblastoma Phase 2
Recruiting NCT01765088 - A Phase III Trial on Adjuvant Temozolomide With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas Phase 3
Completed NCT01836536 - Search for a Link Between Response to Treatment and Circulating Leucocytes in High Grade Glioma Patients N/A
Active, not recruiting NCT01339052 - Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma Phase 2
Completed NCT01493219 - Biomarkers for Prognosis of Glioblastoma (GBM) N/A